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Abstract
Type 2 diabetes (T2D) is characterized by β cell dysfunction and loss. Single nucleotide polymorphisms in the T-cell factor 7-like
2 (TCF7L2) gene, associatedwith T2D by genome-wide association studies, lead to impaired β cell function.While deletion of the
homologous murine Tcf7l2 gene throughout the developing pancreas leads to impaired glucose tolerance, deletion in the β cell
in adultmice reportedly hasmoremodest effects. To inactivate Tcf7l2 highly selectively in β cells from the earliest expression of
the Ins1 gene (∼E11.5) we have therefore used a Cre recombinase introduced at the Ins1 locus. Tcﬂ2ﬂ/ﬂ::Ins1Cre mice display
impaired oral and intraperitoneal glucose tolerance by 8 and 16 weeks, respectively, and defective responses to the GLP-1
analogue liraglutide at 8 weeks. Tcﬂ2ﬂ/ﬂ::Ins1Cre islets displayed defective glucose- and GLP-1-stimulated insulin secretion and
the expression of both the Ins2 (∼20%) and Glp1r (∼40%) genes were signiﬁcantly reduced. Glucose- and GLP-1-induced
intracellular free Ca2+ increases, and connectivity between individual β cells, were both lowered by Tcf7l2 deletion in islets from
mice maintained on a high (60%) fat diet. Finally, analysis by optical projection tomography revealed ∼30% decrease in β cell
mass in pancreata from Tcﬂ2ﬂ/ﬂ::Ins1Cremice. These data demonstrate that Tcf7l2 plays a cell autonomous role in the control of β
cell function andmass, serving as an important regulator of gene expression and islet cell coordination. The possible relevance
of these ﬁndings for the action of TCF7L2 polymorphisms associated with Type 2 diabetes in man is discussed.
Introduction
A considerable bodyof evidence suggests there is a strong heredi-
tary component to type 2 diabetes (T2D) (1–3). Indeed, genome-
wide association studies (GWAS) have now identiﬁed over 90
loci that are associated with T2D risk (reviewed in 4). Most of
the identiﬁed single nucleotide polymorphisms (SNP) associated
with T2D appear to affect β cell mass or function (5). However,
most of these are in intronic or intergenic regions, making it dif-
ﬁcult to identify the causal gene(s) and thus the impact of the
identiﬁed SNP(s) at the molecular and cellular level (6).
Recently, much effort has been devoted to elucidating how
the T2D-associated SNP rs7903146, which lies in intron 3 of the
T-cell factor 7 like-2 (TCF7L2) gene, may lead to increased risk of
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diabetes. First described in Icelandic, Danish and US cohorts (7)
SNP rs7903146 is presently the most strongly associated of the
GWAS-identiﬁed variants with T2D (7–10) and is also associated
with latent autoimmune diabetes in adults (11). Available clinical
evidence points to an action of the risk alleles to impair insulin
secretion in man with little, or a slightly protective effect, on
insulin action (7–19).
TCF7L2 is a member of the TCF family of transcription factors
involved in the control of cell growth and signalling downstream
of wingless-type MMTV integration site family (Wnt) receptors
(20) and was previously best known for its association with pros-
tate and colon cancer development (21,22). Activation of theWnt
pathway leads to release of catenin from an inhibitory complex
and its translocation to the nucleus, where it binds TCF7L2 and
other related TCF factors (23). The function of this transcriptional
complex is context dependent, i.e. it may act as either a transcrip-
tional activator or repressor (5,23). In the pancreas, TCF7L2 and the
Wnt signalling pathway are essential for proliferation of the pan-
creatic epithelium (24) and enhanced Wnt signalling has been
shown to lead to islet proliferation (25). While loss of β-catenin
signalling leads to pancreatic hypoplasia (26), stabilization of
β-catenin results in the formation of large pancreatic tumours (27).
Studies from our own laboratory and others’ have shown that
silencing of Tcf7l2 gene expression in clonal cell lines (28) and pri-
mary islets (28,29) leads to increased apoptosis and impaired
β cell function. Moreover, LoxP-mediated deletion speciﬁcally in
the pancreas using a PDX1.Cre (30), led to glucose intolerance
and impaired β cell mass on a high fat diet. On the other hand,
a recent report (31) indicated that whereas deletion in the liver
led to lowered hepatic glucose output, consistent with earlier
ﬁndings of perinatal mortality in global Tcf7l2 null mice (32), de-
letion in the β cell in adult mice using a tamoxifen-inducible rat
insulin promoter 2-driven (RIP2.Cre-ERT2) deleter strain exerted
no apparent effect on glucose homeostasis. The authors there-
fore concluded that changes in Tcf7l2 expression in the β cell in
man are unlikely to contribute to diabetes risk. However, the lat-
ter studies were limited to the examination of relatively young
(<12 weeks old) mice maintained on a normal chow diet. More-
over, deletion in adults precluded examination of the effects on
β cell proliferation during early post-natal growth. Finally, it
was unclear in these studies whether Tcf7l2 expression was af-
fected in the hypothalamus of the resulting KO mice, as might
be expected using the Pdx1.Cre line (33).
Gene expression analysis following Tcf7l2 deletion or silen-
cing revealed changes in the expression of a number of genes
in mouse pancreatic islets, including that encoding the GLP-1 re-
ceptor (Glp1r; (15,28,30,34). Correspondingly, it has previously
been reported that TCF7L2maymediate GLP-1-induced β cell pro-
liferation (35). Since GLP-1 has also been implicated in β cell sur-
vival, the increased incidence of apoptosis in TCF7L2-silenced
islets (29,36), and in individuals carrying the risk variants of
TCF7L2 (15), are both consistent with lowered GLP-1 signalling
(15,36). Supporting this view is the decrease in β cell mass in
high fat-fed, pancreas-speciﬁc Tcf7l2 null mice (30) and in mice
over-expressing a dominant negative form of Tcf7l2 in β cells
(37). Thus, the diminished insulinotropic effect of GLP-1 in islets
lacking Tcf7l2 activity seems likely to be due, at least in part, to a
lack of cognate receptors on the cell surface (28,30,37). Dimin-
ished brain GLP-1 signalling in mice over-expressing a dominant
negative form of Tcf7l2was also reported to lead to impaired glu-
cose tolerance and insulin sensitivity when mice were adminis-
tered a high fat diet (38).
While the above evidence suggests that loss of Tcf7l2 from the
β cell is likely to impair insulin production, and hence increase
T2D risk, adult Tcf7l2 knockout mice show reduced hepatic
glucose production during fasting and improved glucose homeo-
stasis when maintained on a high fat diet (31); loss of Tcf7l2 sig-
nalling in the liver is associatedwith lowered expression of genes
involved in glucose metabolism in this tissue (31,39). Such data
together indicate that lowering Tcf7l2 activity, at least in the
liver, may be beneﬁcial in metabolic diseases. Moreover, it has
also been reported that transgenic mice over-expressing TCF7L2
systemically have impaired glucose homeostasis, among other
physiological anomalies (40). The latter data are consistent with
those from Gaulton et al. (41), indicating that chromatin at the
TCF7L2 gene is in an islet-speciﬁc ‘open’ conformation, and that
in β cell lines the enhancer activity of the at-risk T-allele is ele-
vated compared with the C-allele. Moreover, Savic et al. (42)
have identiﬁed tissue-speciﬁc enhancer activity within the asso-
ciation interval of rs7903146 which may lead to the generation
of different splice variants of TCF7L2, potentially leading to differ-
ent functional effects in different tissues. Thus, the apparent
discordance between the metabolic phenotype of the various
mouse models could be partly due to the involvement of
TCF7L2 in glucose homeostasis in more than one tissue, poten-
tially in opposing directions. Further complicating the potential
actions of genomic risk loci, TCF7L2 is subject to tissue-speciﬁc
alternative splicing (43–46).
Given the existing controversy in the literature over the rela-
tive importance of Tcf7l2 in the β cell versus the liver and other
tissues (30,31), and the contributions of extrapancreatic tissues
to the action of risk variants on diabetes risk (47), the present
study was designed to achieve highly selective deletion of
Tcf7l2 in the β cell, from the earliest possible stages in the estab-
lishment of a deﬁnitive β cell status, i.e. expression of the insulin
gene. To this endwehave used a highly β cell selective Cre recom-
binase, based on expression of the enzyme from the Ins1 locus. In
contrast to the use of Pdx1- (30) or Pdx1ER-based Cres (31) this
strategy allows recombination highly selectively and early in
the development of individual β cells, without the complications
of deletion in other tissues including the brain (33,48).
We show (a) that β-cell deﬁcient Tcf7l2mice show impaired in-
sulin release and glucose homeostasis, particularly in response
to oral glucose challenge; (b) when examined in intact islets, an
unsuspected action is observed on both intracellular calcium sig-
nalling and cell–cell communication, likely to contribute to the
deranged insulin secretion in vivo. These ﬁndings provide further
evidence for the β-cell autonomous role of Tcf7l2, and imply that
this factor maybe particularly important during expansion of
these cells in the post-natal period or during adaptation tometa-
bolic stresses including high fat diet
Results
Abnormal glucose tolerance and insulin secretion in β cell
selective Tcf7l2 null mice
In the present study, we used Ins1.Cre mice (48) (B. Thorens and
J. Ferrer, manuscript in preparation) to effect highly selective and
early (∼E11.5) (49,50) deletion of Tcf7l2 in β cells, based on Cre ex-
pression driven by the Ins1 gene (33,51). The resultant Tcf7l2 null
(Tcf7l2ﬂ/ﬂ::Ins1.Cre+) mice were born at the expected Mendelian
ratio and gained weight similarly to wild-type mice (Tcf7l2ﬂ/ﬂ::
Ins1.Cre−) when maintained on regular chow (Supplementary
Material, Fig. S1).
As shown in Figure 1A–D, Tcf7l2ﬂ/ﬂ::Ins1.Cre+ mice developed
impaired intraperitoneal glucose tolerance in an age-dependent
manner, displaying signiﬁcant impairments from 16 weeks
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(increase in AUC of 13.6 ± 2.8%, n = 6 mice per genotype, P < 0.05).
Impaired oral glucose tolerance (increase in AUC of 10.6 ± 1.3%,
n = 6, P < 0.05) was apparent in younger animals (from 8 weeks;
Fig. 1E). Consistent with amoremarked effect via altered incretin
responses, the glucose excursion prompted by elevated glucose
(1 g/kg) plus the GLP-1 analogue liraglutide (200 µg/kg) (52) was
particularly strongly affected by Tcf7l2 deletion (Fig. 1F). These
changes were not associated with any alteration in sensitivity
to intraperitoneal insulin (Fig. 1G).
To determine whether the imposition of a metabolic stress
may affect the glucose intolerance observed in Tcf7l2ﬂ/ﬂ::Ins1.Cre+-
mice, animals weremaintained for the indicated times on a high
fat (∼60% total calories) diet. Null animals under these conditions
gained weight similarly to wildtype littermates, albeit with a
small increase versus controls apparent from 20 weeks (Supple-
mentary Material, Fig. S1). While glucose intolerance was not ap-
parent at 12 weeks (Fig. 1B), the dysglycemia observed at 16 and
20 weeks was further exaggerated compared with that apparent
Figure 1. Glucose and insulin tolerance in Tcf7l2ﬂ/ﬂ::Ins1.Cre+mice. Intraperitoneal glucose tolerancewas assessed at 8 (A), 12 (B), 16 (C) and 20 (D) weeks of age in Tcf7l2ﬂ/ﬂ::
Ins1.Cre+(blue) and Tcf7l2ﬂ/ﬂ::Ins1.Cre− (black dotted)micemaintained on a normal chow diet (ND), and Tcf7l2ﬂ/ﬂ::Ins1.Cre+(red) and Tcf7l2ﬂ/ﬂ::Ins1.Cre− (black)maintained on
a high fat (HFD; 60%) diet. Glucose tolerance and area under the curve (inset) are shown. Oral glucose tolerance was assessed at 8 weeks in mice maintained on a normal
chow diet (E). Intraperitoneal glucose (1 g/kg) tolerance and response to liraglutide (200 µg/kg) treatment (F) and insulin (0.75 units/kg) tolerance (G) was assessed at 20
weeks in mice maintained on a normal chow diet. (H) Fasting plasma glucagon concentration was measured on mice fed on a HFD (see Materials and Methods) n = 7–10
mice; *P≤ 0.05.
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in animals maintained on regular chow (Fig. 1C and D). Insulin
tolerance did not differ between genotypes (Fig. 1G), and fasting
glucagon levels were identical (Fig. 1H). Nonetheless, in vivo insu-
lin release prompted by IP injection of 1 g/kg glucose was mark-
edly impaired in the null mice (Fig. 2A).
Conﬁrming recombination in the β cell compartment, qRT-
PCR revealed ∼75% decrease in the expression of Tcf7l2 in the
islet (Fig. 2B). This was associated with decreased expression of
both Ins2 and Glp1r (Fig. 2B).
Consistentwith the impaired glucose tolerance observed in vivo,
islets of Langerhans isolated from Tcf7l2ﬂ/ﬂ::Ins1.Cre+ mice at
20 weeks displayed impaired glucose (P < 0.05) and GLP-1-(P < 0.05)
stimulated insulin secretion versus islets from control Cre- mice
(Fig. 2C). These effects were even more marked in islets extracted
from high fat-diet treated animals (Fig. 2D), where the effects of
GLP-1 to potentiate those of 17 m glucose were completely
abolished.
Effects of Tcf7l2 elimination on glucose and
GLP-1-induced intracellular free Ca2+ dynamics
and β cell connectivity
In healthy β cells, high glucose induces elevations in intracellular
ATP/ADP ratio, the closure of ATP-sensitive K+ channels and the
opening of voltage-gated Ca2+ channels to increase intracellular
(cytosolic) free calcium ([Ca2+]cyt) (53,54). To further explore the
mechanisms underlying the altered secretory responses in Tcf7l2
null β cells we therefore determined whether glucose-induced
[Ca2+]cyt dynamics may be affected. Examined in whole islets
from normal diet-fed mice by functional multicellular imaging
(55–57), we observed largely unaltered responses to glucose of
individual β cells after Tcf7l2 elimination (Fig. 3A and C). In con-
trast, those in response to GLP-1 were signiﬁcantly impaired,
with the proportion of GLP-1-responsive cells markedly reduced
(Fig. 3C). On the other hand, after maintenance on a high fat
diet, both the amplitude of the [Ca2+]cyt response to high glucose
(Fig. 3B), and the proportion of cells responding to GLP-1
(Fig. 3D), were reduced in Tcf7l2ﬂ/ﬂ::Ins1.Cre+ mice versus controls.
Changes in β cell ‘connectivity’, i.e. the degree to which β cells
across the islet syncytiummount a coordinated (synchronized) re-
sponse to stimulation (56), are associated with impaired insulin
secretion (55). We have also recently demonstrated that human β
cells depleted for another GWAS gene for T2D, adenylate cyclaseV
(ADCY5) (57), show impaired cellular connectivity. Whereas Tcf7l2
elimination exerted no effect on the number of connected cell
pairs in islets from normal chow-fed mice (Fig. 3E), inter-cellular
connectivity was signiﬁcant reduced by loss of this transcription
factor from islets maintained on a high fat diet (Fig. 3F and G).
Effects of Tcf7l2 elimination on β cell expansion in
response to high fat diet
To determine whether alterations in β (or α) cell mass also might
contribute to impaired insulin production in vivo after Tcf7l2
Figure 2. Tcf7l2 deletion impairs glucose and GLP1-stimulated insulin secretion from isolated islets. (A) Plasma insulin following intraperitoneal injection of glucose from
20-week-old mice that had been maintained on a high fat diet was measured as described in Materials and Methods. (B) Real-time quantitative PCR analysis was
performed on islets from 20-weeks-old mice that had been maintained on a normal chow diet. n = 7–10 mice; *P ≤ 0.05. (C and D) Insulin secretion as assessed in
isolated islets from 20-week old Tcf7l2ﬂ/ﬂ::Ins1.Cre+(red) and littermate Tcf7l2ﬂ/ﬂ::Ins1.Cre− (black) mice on normal chow (C) or high fat diet (D). n = 5 mice per genotype;
*P≤ 0.05; **P≤ 0.01.
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elimination, pancreata from 20-week-old Tcf7l2ﬂ/ﬂ::Ins1.Cre+mice
that had been maintained on a HFD for 12 weeks were stained
for insulin and glucagon, respectively, and analyzed by optical
projection tomography (OPT). Cre+ islets displayed a markedly
(31.7%, P < 0.05; n = 4 mice per genotype) decreased β cell mass,
but normal α-cell mass, compared with littermate controls
(Fig. 4), resulting in an overall decrease in β to α cell ratio. The
number of smaller insulin-stained islets was particularly sharply
decreased in TCF7L2ﬂ/ﬂ::Ins1.Cre+ mouse islets (Fig. 4B).
Discussion
The chief goal of the present studieswas to reassess the role in the
β cell of theWnt signalling dependent transcription factor TCF7L2.
Using a Cre that is highly selective for the mature β cell (48)
(B. Thorens and J. Ferrer unpublished), our ﬁndings show ﬁrstly
that this factor is required for (a) the normal function of these
cells, and (b) their expansion under a situation ofmetabolic stress.
Moreover, we provide novel insights into the role of Tcf7l2 in the
control of intracellular Ca2+ dynamics and β cell–β cell communi-
cation. The latter result was unexpected given previous ﬁndings
that [Ca2+]cyt changes were apparently unaffected by manipula-
tion of Tcf7l2 expression (28). However, the earlier studies were
performed using isolated β cells (or small clusters of cells) rather
than intact islets as examined here, where complex inter-cellular
cross-talk is likely to overlay cell-intrinsic responses to stimula-
tion. Nonetheless, the present results are consistent with very
recent ﬁndings (58) showing decreased expression of the volt-
age-gated calcium channel subunits including Cacna1d in rat
insulinoma-derived INS1 β cells silenced for Tcf7l2.
Figure 3. Impact of Tcf7l2 deletion on intra- and inter-cellular Ca2+ dynamics. (A and C) Responses to glucose (17 m; G17) or GLP-1 (100 n) of β cells within intact islets of
Tcf7l2ﬂ/ﬂ::Ins1.Cre+(red) and Tcf7l2ﬂ/ﬂ::Ins1.Cre− (black)micemaintained on a normal chowdiet. (B andD) as for (A and C) but for islets fromanimalsmaintained for 12weeks
on a 60% fat diet. Correlation analysis (55,56) for islets frommice maintained on (E) normal diet and (F) high fat diet, and (G) quantitation of changes in typical islets from
Tcf7l2ﬂ/ﬂ::Ins1.Cre+ and Tcf7l2ﬂ/ﬂ::Ins1.Cre− mouse islets as indicated.
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How might TCF7L2 control β cell connectivity? While the dis-
ruption of connectivity in earlier studies, e.g. after exposure to li-
potoxic conditions (55), could be ascribed to impairments in the
expression of the gap junction protein connexin 36 (Gjd2), we
were unable to detect changes in Gjd2 mRNA in Tcf7l2 null islets
in the present study (Fig. 2B), consistent with an earlier study in-
vestigating the role of Wnt signalling in the expression of other
gap junction proteins (59). Changes in level or post-translational
modiﬁcations (60) of this protein nonetheless remain a possibil-
ity as, of course do changes in the expression of other genes.
There is gathering evidence to suggest that the effect of
TCF7L2 is mediated by resistance to incretin treatment at the
level of the β cell (15,16,61–63). The present studies provide fur-
ther support for this view showing both marked alterations in
the expression of the Glp1r gene in Tcf7l2 null islets (Fig. 2B),
and impaired glucose-stimulated insulin secretion (Fig. 2C and D).
Whether reduced numbers of these receptors on β cells also
contributes to the apparent impairment in β cell expansion in
the face of a high fat diet is unknown, but would seem worthy
of future investigation.
A particularly signiﬁcant ﬁnding of the present study was the
appearance in Tcf7l2ﬂ/ﬂ::Ins1.Cre+ mice of glucose intolerance
from 16 weeks onwards demonstrating that the appearance of a
β cell phenotype is dependent on age or other stresses. Import-
antly, in recent studies (31), the effects of Tcf7l2 inactivation in
the adult mouse β cell (using an alternative model in which
exon 10, encoding the DNA-binding HMG box, was deleted)
were not examined beyond 12 weeks of age, such that any effects
later in life would have been missed. Of note, in the model
described here, placing mice on a high fat diet increased the
extent of the intolerance but did not bring forward its appearance
substantially (Fig. 1).
Figure 4. Impact of Tcf7l2 deletion on β and α cell mass. (A) Representative 3D images from OPT (see Material and Methods) of Tcf7l2ﬂ/ﬂ::Ins1.Cre+ and Tcf7l2ﬂ/ﬂ::Ins1.Cre−
pancreata labelled with anti-insulin and anti-glucagon primary antibodies, and revealed using AlexaFluor 568 and 680, respectively. Right hand-most panels are
overlaid with the autoﬂuorescence signal revealing the pancreatic ductal system. Quantiﬁcation of β (B), α (C) and (D) β/α cell mass from Tcf7l2ﬂ/ﬂ::Ins1.Cre+(red) and
Tcf7l2ﬂ/ﬂ::Ins1.Cre− (black) knockout mice pancreata from 20-week-old mice that had been maintained on high fat diet. Quantiﬁcation was conducted using Volocity
software (Invitrogen), N = 4 mice per genotype.
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Relevance of the present ﬁndings for understanding of
the action of TCF7L2 T2D risk variants in man
We have previously speculated (6) that variants at rs7903146 and
neighbouring SNPs may have differential effects on TCF7L2
expression the liver and on β cells as a result of differing splicing
patterns in the two tissues. In particular, alternative splicing at
the boundaries of exon 13, 13b and 14 leads to the loss of a
‘CRARF’ motif that appears to be selectively expressed in the β
cell and susceptible to modulation by the risk T allele (34).
Thus, a decrease in TCF7L2 activity at the protein level may be
observed in islets from T-allele carriers despite increases in the
overall levels of TCF7L2 transcripts. Thus, the expression of mul-
tiple Tcf7l2 alleles globally in mice (40), or forced inactivation of
Tcf7l2 in the liver (31), with its consequent dramatic effect to
impair hepatic glucose output, may be of limited relevance to
the action of the human SNP. In contrast, the impact of lowered
Tcf7l2 levels in the β cell, at least during the stresses imposed
by aging or high fat feeding, may be more pertinent. Thus, as
shown by the present studies, these are likely to act at the
same time on the secretory activity of single β cells (28), the co-
ordination of these cells within the islet (likely to further impair
insulin output) (55), and ﬁnally on β cell mass. Nonetheless,
further studies exploring in detail the relationship between
Tcf7l2 action in different tissues would seem to be warranted.
On a ﬁnal note, ‘mice are notmen’ and that, given recent ﬁnd-
ings in relation to the consequences of Slc30a8 deletion (64,65), a
certain degree of circumspection is required in transposing ﬁnd-
ings from one to the other. There is currently no compelling evi-
dence, other than immediate genomic proximity, tying TCF7L2 to
the T2D-associated variants, and it remains formally possible,
though rather unlikely, that the GWAS signal is mediated via
another gene. Our new study reinforces the evidence (though
does not prove) that TCF7L2 is the causal gene at this locus.
Material and Methods
Materials
All general chemicals and tissue culture reagentswere purchased
from Sigma (Dorset, UK) or Invitrogen (Paisley, UK), unless
otherwise stated in the text.
Animals
All in vivo procedures were approved by the UK Home Ofﬁce
according to the Animals (Scientiﬁc Procedures) Act 1986 and
were performed at the Central Biomedical Service, Imperial
College, London, UK Rodents were culled by cervical dislocation.
Mice were housed at two to ﬁve animals per cage in a pathogen-
free facility with a 12-h light–dark cycle. Animals were fed
ad libitum with a standard mouse chow diet (Research Diet,
New Brunswick, NJ) unless otherwise stated. For high fat diet
treatment, mice were placed on a high fat diet at 8 weeks of age
for 8 weeks (60% [wt/wt] fat content; Research Diet, New Bruns-
wick, NJ, USA) prior to analysis. Mice were weighed weekly
from eight weeks.
Generation and characterization of β cell-speciﬁc Tcf7l2
knockout mouse
Generation ofmice carrying conditional knockout alleles of Tcf7l2
(Tcf7l2ﬂ/ﬂ) was as described in (30). All mouse strains were main-
tained on a C57BL/6 background. Tcf7l2ﬂ/ﬂmicewere crossedwith
mice expressing Cre recombinase under the control of the Insulin
1 promoter (Ins1.Cremice; (48), J. Ferrer, B. Thorens, unpublished)
to generate Tcf7l2 conditional knockout mice where exon 1 of the
Tcf7l2 gene was removed selectively by Cre-mediated excision
in pancreatic β cells (Tcf7l2ﬂ/ﬂ::ins1.Cre+). Mice were born at
the expected Mendelian ratios with no obvious abnormalities.
Genotyping was performed by PCR using DNA from ear biopsies.
Ablation of Tcf7l2 gene expression from pancreatic islets was
assessed by real-time quantitative PCR (qPCR) on islet RNA, as
described below.
Oral and intraperitoneal glucose tolerance test, insulin
tolerance test
Glucose tolerance was assessed by oral and intraperitoneal
administration of glucose (1 g/kg). Responsiveness to incretin
treatment was assessed by co-injection of liraglutide [200 µg/kg
(66); Bachem, Bubendorf, Switzerland] with glucose during an
intraperitoneal glucose tolerance test. Mice were fasted for 16 h,
with water available ad libitum. Glucose tolerance tests were con-
ducted at 09:00 on each experimental day. Intraperitoneal insulin
tolerance (075Units per kg) testwasperformedasdescribed in (67).
Measurement of plasma hormones
Plasma glucagon frommice fasted for 16 h were measured using
radioimmunoassay (Millipore, Watford, U.K.). Blood (200 µl) was
removed by cardiac puncture frommice killed by cervical disloca-
tion. Plasmawas collected using high speed (2000 g, 5 min at 4°C)
centrifugation in heparin-coated Microvette® tubes containing
EDTA (Sarstedt, Leicester, U.K.) with added DPP IV inhibitor
(100 µM; Millipore, Watford, UK). For measurement of plasma in-
sulin following intraperitoneal injection of glucose, blood (100 µl)
was removed from the tail vein at various times points and plas-
ma collected as described above. Plasma glucagon and insulin
was measured by radioimmunoassay (Millipore).
Quantitative real-time PCR analysis
Primers were designed using Primer Express 3.0 (ABI, CA, USA).
Speciﬁcity for all primers was veriﬁed using BLAST (http://www.
ncbi.nlm.nih.gov/blast/). RNAwas extracted using Trizol (Invitro-
gen, UK). cDNA conversion was performed using High Capacity
cDNA conversion kit (ABI, UK) after DNAse treatment (Ambion,
TX, USA). Real-time PCR was performed on an ABI-Prism Fast
7500 device using powerSYBR reagent (ABI, UK). The primer
sequences used were: Tcf7l2 (forward) TTCCCCCTTGACCTCC
TAGTC, Tcf7l2 (reverse) GCACACGGTCAGTCCATGTT, Ins2 (for-
ward) AGCCCTAAGTGATCCGCTACAA, Ins2 (reverse) CATGTTG
AAACAATAACCTGGAAGA, Glp1r (forward) CCACGGTGTCCCTCT
CAGA, Glp1r (reverse) ACTGCCGCCGGTATTCTCT, Gjd2 (forward)
CCCAGTCTCTGTTTTATCACCTATTCT, Gjd2 (reverse) CGGCGTTC
TCGCTGCTT.
Insulin secretion assay
Secreted insulin from groups of six pancreatic islets of Langer-
hans was measured by radioimmunoassay (Linco, MA, USA) as
previously described (68,69).
Calcium imaging and correlation analysis
Calcium imaging and correlation analysis were performed as
described in (55).
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Optical projection tomography and calculations of
relative α and β cell mass
Whole pancreatic OPT, to 19 µm resolution, was performed as
previously described (67,70). Dual labelling for insulin and gluca-
gon was performed using anti-insulin antibody (DAKO) and anti-
glucagon antibody (Sigma) revealed using Alexa Fluor 568 and
680 (Invitrogen), respectively.
Statistical analysis
Values presented are the mean ± SEM for the number of observa-
tions indicated. Statistical signiﬁcance and differences between
means were assessed by a two-tailed Student’s t test or one-
way ANOVA with Bonferroni correction for multiple analyses.
Linear correlations were calculated using regression analyses.
Analysis was performed using Excel™, R, GraphPad Prism
(GraphPad Software) and IgorPro.
Supplementary Material
Supplementary Material is available at HMG online.
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